Why I Set the Primary Endpoint of My Clinical Trial at a 95% Complete Response Rate

A Methodological Explanation Based on the Intratumoral Chlorine Dioxide Ablation System

I am currently designing a clinical trial for the Intratumoral Chlorine Dioxide Ablation System, regulated as a medical device under the Chinese regulatory framework.

In this trial, I have chosen Complete Response (CR) rate as the primary clinical endpoint, with a target level of 95% CR.

This decision is neither aggressive nor a challenge to regulatory orthodoxy. Rather, it is a rational choice derived directly from the technical characteristics, risk structure, and predictability of the system itself.

This article aims to address three core questions:

1. Why complete response rate is the appropriate endpoint for this system

2. Why 95% CR is a realistic, designable, and verifiable target

3. Why, in this treatment paradigm, CR is superior to Overall Survival (OS)—the endpoint currently favored by the FDA

---

I. Clinical Endpoints Must Derive from System Properties, Not Historical Convention

A clinical endpoint is not an abstract preference; it is the natural output of an engineering system.

The Intratumoral Chlorine Dioxide Ablation System differs fundamentally from conventional cancer treatments in several key ways.

---

1. Simple delivery and repeatability

This system relies on intratumoral injection.

It does not require complex equipment or a single, irreversible “maximal intervention.”

Under image guidance, injection paths are clear, reproducible, and repeatable.

This means the treatment is not a one-shot gamble, but an iterative, correctable process.

---

2. Self-limiting reaction and minimal side effects

Chlorine dioxide acts through direct-contact chemical reactions within tumor tissue.

Once the reaction completes, it terminates naturally and does not propagate systemically.

As a result:

• Damage to normal tissue is minimal

• There is no cumulative systemic toxicity

• Repeated injections do not increase risk

This risk profile fundamentally allows multiple corrective interventions.

---

3. Clear dose–effect boundaries without proportional risk escalation

Chlorine dioxide works through two tightly coupled mechanisms:

• Direct oxidative destruction of tumor cells

• Vascular disruption leading to secondary ischemic tumor necrosis

Because its effective boundary is determined by contact range and tissue structure, rather than circulating concentration, the system allows:

Dosing within a region where efficacy is sufficient while risk does not increase.

This is an engineered, controllable system, not a probabilistic escalation model.

---

4. Rapid structural collapse without inflammation, with hemostatic and anti-infective effects

Unlike radiotherapy or many thermal ablation techniques, this system:

• Rapidly reduces tumor volume

• Does not provoke significant inflammatory response

• Provides intrinsic hemostatic and anti-infective effects

This allows tumors to be fully eliminated, rather than entering a prolonged cycle of inflammation, repair, and recurrence.

---

Conclusion 1

Based on these properties, the system naturally satisfies a critical condition:

Treatment outcomes can be iteratively corrected until complete response is achieved, without a meaningful increase in risk.

Therefore, complete response is not an aggressive endpoint—it is the natural endpoint of the system.

---

II. What “Complete Response Rate” Means—and Why It Is a System-Level Endpoint

Complete Response (CR) does not mean “a single tumor disappears.”

It represents a system-level disease state.

In this clinical context, CR is defined as:

• Complete disappearance of all evaluable tumor lesions

• No emergence of new active disease

• Sustained stability over a predefined follow-up window

This reflects termination of disease behavior at the system level, not merely local technical success.

---

Why historical local therapies failed to achieve system-level CR

• Surgery treats only known lesions

• Radiotherapy and ablation are locally effective but systemically incomplete

• Local injections have historically been limited by toxicity or inflammation

These modalities are structurally incapable of iterative system correction.

---

Why systemic drug therapies rarely achieve CR

• Drug effects are probabilistic and distribution-dependent

• Dosing is constrained by systemic toxicity

• Outcomes are typically:

  • Partial response (PR)

  • Stable disease (SD)

  • Prolonged survival, but rarely complete eradication

This is why OS became their default endpoint.

---

Conclusion 2

The historical scarcity of CR is not because it is unimportant, but because existing tools do not allow it to be a routine outcome.

The Intratumoral Chlorine Dioxide Ablation System changes this premise.

---

III. Why CR Is Superior to OS in This Treatment Paradigm

Overall Survival (OS) is currently favored by the FDA, but it is not an absolute truth—it is a historical compromise.

---

What OS actually represents

OS became dominant when:

• Disease eradication was unreliable

• Progression could only be delayed

• Recurrence was nearly inevitable

Under these conditions, survival time was the only stable measurable outcome.

---

The intrinsic limitations of OS

1. Severely diluted causality

   OS is affected by subsequent therapies, supportive care, and unrelated complications.

2. Low information density

   It requires long time horizons and provides little mechanistic insight.

3. Failure to distinguish disease termination from delay

   OS extension does not imply the disease has been eliminated.

---

In a low-toxicity, repeatable, predictable system, OS becomes a suboptimal endpoint

When a system allows:

• Repeated interventions

• Non-cumulative risk

• Outcome correction

Using OS as the primary endpoint avoids measuring what the system actually does best.

---

Conclusion 3

When a treatment is designed to terminate disease rather than merely delay it,

CR is the most direct, information-dense, and causally honest endpoint.

---

IV. Why 95% CR Is a Reasonable Target

The 95% CR target is not a promotional figure—it is an engineering objective.

It allows for:

• Anatomical variability

• Tumor complexity

• A small margin of irreducible uncertainty

Yet it makes one statement unambiguous:

Complete response is not an exception; it is the expected system outcome.

If a treatment system is:

• Bounded

• Low-risk

• Repeatable

• Correctable

then setting a 95% CR target is not exaggeration—it is respect for the system’s capabilities.

---

Conclusion

The choice of a clinical endpoint reflects not ambition, but understanding of the intervention itself.

When a therapeutic system fundamentally changes risk structure, intervention logic, and predictability, there is no justification for continuing to use endpoints designed for older, inferior tools.

Complete response is not a more aggressive endpoint.

It is a more honest one.